Literature DB >> 4009375

Evaluation of the role of surgery in 130 patients with neuroblastoma.

J N Le Tourneau, J L Bernard, W H Hendren, M Carcassonne.   

Abstract

The role of surgery for children with neuroblastoma was evaluated by using a recently proposed TNM staging system. One-hundred thirty patients were retrospectively assigned a TNM clinical stage (CS) preoperatively and a pathologic stage (PS) postoperatively. Patients with CS 4 were separated into CS 4A and CS 4B according to their age and pattern of metastases. Patient survival was analyzed according to CS, age, location of primary, and PS. Actuarial survival of patients was as follows: CS 1, 100%; CS 2, 82%; CS 3, 63%; CS 4A, 50%; and CS 4B, 5%. For all stages, patients younger than 1 year old survived longer than those older than 1 year (72% v 32%). Prognosis for CS 1 was the same regardless of age. For CS 2 and CS 3, patients younger than 1 year old lived longer. CS 4A had better survival than CS 4B. Survival by site was 100% for cervical, 62% for mediastinal, 45% for pelvic, and 36% for retroperitoneal primaries. The role of surgery was evaluated by analyzing survival according to the postoperative PS. PS 1-2-3 A were regarded as satisfactory resections since all macroscopic tumor was removed. PS 3B as a debulking procedure, and PS 3C as an unresectable lesion which was biopsied. Patients with nonmetastatic disease (CS 1-3) with PS 1 and PS 2 disease had a 100% survival rate; PS 3A, 93%; PS 3B, 58%; and PS 3C, 21%. This proves the value of total resection in nonmetastatic disease. The role of surgery could also be proven in metastatic disease.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1985        PMID: 4009375     DOI: 10.1016/s0022-3468(85)80113-5

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  8 in total

1.  Delayed surgery and bone marrow transplantation for widespread neuroblastoma.

Authors:  T J Moss; E W Fonkalsrud; S A Feig; C Lenarsky; M Selch; J Wells; R C Seeger
Journal:  Ann Surg       Date:  1987-10       Impact factor: 12.969

2.  Prognostic value of different staging systems in neuroblastomas and completeness of tumour excision.

Authors:  N L Carlsen; I J Christensen; H Schroeder; P V Bro; U Hesselbjerg; K B Jensen; O H Nielsen
Journal:  Arch Dis Child       Date:  1986-09       Impact factor: 3.791

3.  Complete surgical resection combined with aggressive adjuvant chemotherapy and bone marrow transplantation prolongs survival in children with advanced neuroblastoma.

Authors:  R S Chamberlain; R Quinones; P Dinndorf; N Movassaghi; M Goodstein; K Newman
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

4.  Surgical management of thoracic malignancy in childhood: eight years' experience in Leeds.

Authors:  J P Lodge; J R Hamilton; D R Walker; C C Bailey
Journal:  Ann R Coll Surg Engl       Date:  1988-03       Impact factor: 1.891

Review 5.  Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95 % tumour resection suffice?

Authors:  S Zwaveling; G A M Tytgat; D C van der Zee; M H W A Wijnen; H A Heij
Journal:  Pediatr Surg Int       Date:  2012-06-22       Impact factor: 1.827

6.  Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).

Authors:  H Rubie; J Michon; D Plantaz; M C Peyroulet; C Coze; D Frappaz; P Chastagner; M C Baranzelli; F Méchinaud; P Boutard; P Lutz; Y Perel; G Leverger; L de Lumley; F Millot; J L Stéphan; G Margueritte; O Hartmann
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

7.  Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study.

Authors:  T Philip; R Ladenstein; J M Zucker; R Pinkerton; E Bouffet; D Louis; W Siegert; J L Bernard; D Frappaz; C Coze
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

8.  Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy.

Authors:  H Rubie; C Coze; D Plantaz; C Munzer; A S Defachelles; C Bergeron; C Thomas; P Chastagner; D Valteau-Couanet; J Michon; V Mosseri; O Hartmann
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.